drugset
Drugs / Cirtuvivint
last change Dec 2025 re-read 2 minutes ago

Cirtuvivint

also known as SM08502

Small molecule

Developed for
acute myeloid leukemia · cancer · castration-resistant prostate carcinoma · colorectal cancer · fallopian tube cancer · myelodysplastic syndrome · non-small cell lung carcinoma · ovarian endometrial cancer
+3 more · primary peritoneal carcinoma · small cell lung carcinoma · soft tissue sarcoma
Investigated by
Biosplice Therapeutics, Inc. · National Cancer Institute (NCI) · Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas · National Institutes of Health (NIH) · TenaRx, Inc. · University of Colorado, Denver
+1 more · Washington University School of Medicine

Trials 6 · a red edge is where a trial was stopped

today NCT07155200 · Ph 1/2 NCT06856499 · Ph 1 NCT06484062 · Ph 1 NCT07032285 · Ph 2 NCT05084859 · Ph 1 NCT03355066 · Ph 1
20182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT06856499 Dec 2025 → Jul 2027 expected fallopian tube cancer, ovarian endometrial cancer, primary peritoneal carcinoma University of Colorado, Denver Recruiting No outcome recorded
Phase 1 NCT06484062 Aug 2025 → Jun 2028 expected acute myeloid leukemia, myelodysplastic syndrome National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1 NCT05084859 Nov 2021 → Oct 2022 castration-resistant prostate carcinoma, colorectal cancer, non-small cell lung carcinoma Biosplice Therapeutics, Inc. Terminated No outcome recorded
Phase 1 NCT03355066 Nov 2017 → Nov 2022 cancer Biosplice Therapeutics, Inc. Terminated No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07155200 Dec 2025 → Jul 2028 expected small cell lung carcinoma Washington University School of Medicine Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07032285 Jan 2025 → Apr 2027 expected soft tissue sarcoma Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Cirtuvivint ClinicalTrials.gov intervention name — accepted as the source's own label NCT06856499 ↗
3

NCT07155200 ↗

NCT07032285 ↗

NCT06484062 ↗
Known as SM08502 “Cirtuvivint (SM08502) is a first in class pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with suspected multiple anti-tumor mechanisms of...” NCT06856499 ↗
3

“Cirtuvivint (SM08502) will be administered orally at 80 mg/day, 5 days on/2 days off.” NCT07032285 ↗

NCT05084859 ↗

NCT03355066 ↗
Action Inhibit “potent inhibition of CDC-like kinase (CLK) activity” PMID 31560935 ↗ Sep 2019
Modality Small molecule “SM08502, a novel small molecule in clinical development for the treatment of solid tumors” PMID 31560935 ↗ Sep 2019
Route Oral “SM08502 tablets to be administered orally.” NCT03355066 ↗